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Increase in hyperglycaemia-induced oxidative stress and decreased eﬀectiveness of endogenous defense mechanisms plays an
essential role in the initiation of diabetes-related neuropathy. We demonstrated that nitrergic myenteric neurons display
diﬀerent susceptibilities to diabetic damage in diﬀerent gut segments. Therefore, we aim to reveal the gut segment-speciﬁc
diﬀerences in the expression of heme oxygenase (HO) isoforms and the colocalization of these antioxidants with neuronal nitric
oxide synthase (nNOS) in myenteric neurons. After ten weeks, samples from the duodenum, ileum, and colon of control and
streptozotocin-induced diabetic rats were processed for double-labelling ﬂuorescent immunohistochemistry and ELISA. The
number of both HO-immunoreactive and nNOS/HO-immunoreactive myenteric neurons was the lowest in the ileal and the
highest in the colonic ganglia of controls; it increased the most extensively in the ileum and was also elevated in the colon of
diabetics. Although the total number of nitrergic neurons decreased in all segments, the proportion of nNOS-immunoreactive
neurons colocalizing with HOs was enhanced robustly in the ileum and colon of diabetics. We presume that those nitrergic
neurons which do not colocalize with HOs are the most seriously aﬀected by diabetic damage. Therefore, the regional induction
of the HO system is strongly correlated with diabetes-related region-speciﬁc nitrergic neuropathy.
1. Introduction
There has been a dramatic increase in the incidence of
various metabolic diseases, like hypertension, obesity, or
diabetes, globally [1–3]. Diabetes mellitus has long been rec-
ognized as the major risk factor of cardiovascular diseases.
Intensive glycemic control has reduced the risks of macro-
and microvascular complications of diabetes; however,
cardiovascular events remain the leading risk factor for mor-
tality of diabetic patients worldwide [3, 4]. In addition to
vascular complications, gastrointestinal (GI) symptoms such
as gastroparesis, abdominal pain, diarrhoea, or constipation
are also very common among diabetic patients. The rela-
tionship between these GI motility abnormalities and the
presence of enteric neuropathy has been well documented
in humans [5–7] as well as in rodent models [8, 9]. We have
also investigated for years the involvement of those nitrergic
myenteric neurons in these GI complications which have a
key role in regulating gut motility. According to our previous
results, the nitrergic neurons located in diﬀerent gut seg-
ments display diﬀerent susceptibilities to diabetic damage
and diﬀerent levels of responsiveness to insulin treatment
[9]. These results highlight the importance of the neuronal
microenvironment along the GI tract in the pathogenesis of
diabetic nitrergic neuropathy. Working towards a better
understanding of the molecular diﬀerences in the neuronal
microenvironment, we have demonstrated that the mesen-
terial capillaries [10] supplying the myenteric ganglia and
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the faeces-associated microbiota [11] are also serious targets
of diabetic injuries in the same rat model. Diabetes-related
microvascular complications and alterations in the composi-
tion of gut microbiota are also region speciﬁc in the diﬀerent
intestinal segments and are closely correlated with region-
dependent nitrergic myenteric neuropathy.
It is well known that hyperglycaemia is clearly the culprit
in the pathogenesis of diabetic complications, and there are
convincing evidences that the onset of diabetes and its symp-
toms are closely associated with oxidative stress [12, 13].
Moreover, hyperglycaemia increases the formation of
advanced glycation end products and inﬂammatory events
[14, 15]. There is also evidence that diﬀerent subpopulations
of myenteric neurons have selective responses to diabetic oxi-
dative stress [16]. Besides an increased formation of reactive
oxygen species (ROS), another main problem is the serious
attenuation of antioxidant defense mechanisms. Among the
endogenous antioxidants, the heme oxygenase (HO) system
is recently emerging as an important player in diabetes and
in GI inﬂammation [17–23]. HO is a microsomal enzyme
with an essential role in heme catabolism producing
biologically active carbon monoxide, biliverdin, and free iron
[21, 24, 25]. Two main isoforms, HO1 and HO2, have been
characterized as products of two diﬀerent genes with distinct
tissue- and cell-speciﬁc expression patterns [24, 26]. HO2 is
considered to be a constitutive isozyme most highly
expressed in neuronal tissues contributing to cell homeosta-
sis, whereas HO1 is thought to be an inducible form with
relatively low expression in most tissues [21, 24, 27]. Induc-
tion of the HO1 protein was shown to protect against a
variety of stress conditions such as ischaemia [28], hypoxia
[29], and ROS [30]. In addition, treatment with antioxidants
minimizes or prevents the development of widespread com-
plications in diabetic patients [31, 32]. The induction of
HO1 decreased ROS, rapidly restored neuronal nitric oxide
synthase (nNOS) expression, and reversed diabetic gastro-
paresis in mice [33]. It has also been reported that induction
of HO1 reduces glomerular injury and apoptosis in diabetic
spontaneously hypertensive rats [34]. In streptozotocin-
(STZ-) induced diabetic rats, HO1 has been found to be
induced in podocytes, protecting against apoptosis [35].
Moreover, in rat ileum, the antioxidant HO2 protects those
NOS-containing neurons from oxidative stress in which it
is colocalized [36]. Due to the beneﬁcent eﬀects of the HO
system [23], these endogenous antioxidants can be the most
important players in the prevention of oxidative injury and
diabetic GI complications. However, HO induction may not
always be beneﬁcial: it can act also as a prooxidant mecha-
nism depending on the disease milieu [37, 38], and the dura-
tion of HO stimulation may be a critical factor in triggering
either the cytotoxic or the adaptive responses [39].
Based on earlier ﬁndings that as a result of the adequate
oxidative environment in the proximal intestine, inducing a
deep anaerobic state in the distal intestine [40, 41], the colon
was more susceptible to damage by oxidative stress [42]; we
supposed that the intestinal region-dependent colocalization
of these endogenous antioxidants with nitrergic myenteric
neurons results in diﬀerent degrees of protection against
chronic hyperglycaemia-induced oxidative stress. Therefore,
our primary aim was to determine the gut segment-speciﬁc
diﬀerences in the expression of the two HO isoforms, HO1
and HO2, and we also planned to evaluate the colocalization
of these antioxidants with nNOS in myenteric neurons of
diﬀerent intestinal segments of chronic diabetic and control
rats. To reﬂect the immediate alterations after the onset of
hyperglycaemia, it was also our goal to study the serum level
of HOs in some early stages of hyperglycaemia.
2. Materials and Methods
2.1. Animal Models. In all procedures involving experimental
animals, the principles of laboratory animal care (NIH Pub-
lication No. 85–23, revised 1985) were strictly followed, and
all the experiments were approved in advance by the Local
Ethics Committee for Animal Research Studies at the Uni-
versity of Szeged. Adult male Wistar rats (Crl: WI BR;
Toxi-Coop Zrt.), kept on standard laboratory chow
(Farmer-Mix Kft., Zsámbék) and with free access to drinking
water, were used throughout the experiments.
2.2. Acute Diabetic Rat Model. For the acute hyperglycaemic
experiments, the rats (250–350 g) were divided randomly
into four groups: STZ-induced 3-day diabetics (n = 5), 5-
day diabetics (n = 5), 10-day diabetics (n = 5), and sex- and
age-matched controls (n = 5). Hyperglycaemia was induced
as described previously [9, 10]. The animals were considered
diabetic if the nonfasting blood glucose concentration was
higher than 18mM. The blood glucose level and weight of
each animal were measured daily.
2.3. Chronic Diabetic Rat Model. For the chronic hypergly-
caemic experiments, the rats (210–260 g) were divided
randomly into two groups: STZ-induced 10-week diabetics
(n = 6) and sex- and age-matched controls (n = 5). Hypergly-
caemia was induced as described previously [9, 10]. The ani-
mals were considered diabetic if the nonfasting blood glucose
concentration was higher than 18mM. The blood glucose
level and weight of each animal were measured weekly
during the 10-week experimental period.
2.4. Blood Collection and Measurement of Serum HO1 and
HO2 Concentrations of Acute and Chronic Diabetic
Animals. The blood samples were collected from the tail vein
of each animal (BD Vacutainer SST II Advance) after 3 days,
5 days, and 10 days as well as 10 weeks of STZ treatment.
Then, they were centrifuged at 3200 rpm for 10min at room
temperature, and the supernatants were stored in aliquots at
−80°C until use. The HO1 and HO2 levels of the serum
samples of acute and chronic diabetic animals were deter-
mined by means of quantitative ELISA according to the man-
ufacturer’s instructions (SunRed Biotechnology, Shanghai,
China). Optical density was measured at 450 nm (Benchmark
Microplate Reader; Bio-Rad, Budapest, Hungary). The serum
HO1 and HO2 concentrations were expressed as ng/ml.
2.5. Tissue Handling. Ten weeks after the onset of hypergly-
caemia, the animals of the chronic diabetic experiment were
killed by cervical dislocation under chloral hydrate anaesthe-
sia (375mg/kg ip). The gut segments of the control and STZ-
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induced diabetic rats were dissected and rinsed in 0.05M
phosphate buﬀer (PB; pH7.4). Samples were taken from the
duodenum (1 cm distal to the pylorus), the ileum (1 cm prox-
imal to the ileocaecal junction), and the proximal colon and
processed for immunohistochemical studies and enzyme-
linked immunosorbent assays (ELISA). For double-labelling
immunohistochemistry, the intestinal segments were cut
along the mesentery, pinched ﬂat, and ﬁxed overnight at
4°C in 4% paraformaldehyde solution buﬀered with 0.1M
PB (pH7.4). The samples were then washed, the mucosa,
submucosa, and circular smooth muscle were removed, and
whole-mounts with the myenteric plexus adhering to the lon-
gitudinal muscle were prepared. For the ELISA, the gut seg-
ments were cut along the mesentery and pinched ﬂat. The
layer of mucosa and submucosa was removed, and the resid-
ual material was snap frozen in liquid nitrogen and stored at
−80°C until use.
2.6. Double-Labelling Fluorescent Immunohistochemistry.
For double-labelling immunohistochemistry, whole-mount
preparations derived from diﬀerent gut segments were
immunostained with nNOS and HO1 or HO2. Brieﬂy,
after blocking of the preparations in PB containing 0.1%
bovine serum albumin, 10% normal goat serum, and
0.3% Triton X-100, they were incubated overnight with
anti-nNOS (rabbit; Cayman Chemical, Ann Arbor, MI,
USA; ﬁnal dilution 1 : 200) and anti-HO1 (mouse; Novus
Biologicals Europe, Abington, UK; ﬁnal dilution 1 : 200)
or anti-HO2 (mouse; Santa Cruz Biotechnology, Inc., Dallas,
Texas, USA; ﬁnal dilution 1 : 50) primary antibodies. After
washing in PB, whole-mounts were incubated with anti-
rabbit Alexa Fluor 488 (Life Technologies Corporation,
Molecular Probes, Inc., Eugene, OR; ﬁnal dilution 1 : 200)
and antimouse Cy™3 (Jackson ImmunoResearch Laborato-
ries Inc., Baltimore Pike, PA; ﬁnal dilution 1 : 200) second-
ary antibodies for 4 hours. All incubations were carried
out at room temperature. Negative controls were performed
by omitting the primary antibody, when no immunoreactiv-
ity was observed. Whole-mounts were mounted on slides in
EverBrite™ Mounting Medium (Biotium, Inc., Hayward,
CA), observed and photographed with an Olympus BX51
ﬂuorescent microscope equipped with an Olympus DP70
camera. Fifty myenteric ganglia were taken from each intesti-
nal segment from each experimental group, and the numbers
of nNOS-IR, HO1- or HO2-IR neurons, and those myenteric
neurons in which the two markers were colocalized (per
ganglia) were counted. The percentage of ganglia contain-
ing HO-IR or nNOS-HO-IR neurons or none of these was
also determined.
2.7. Measurement of Tissue HO1 and HO2 Concentrations.
The intestinal tissue samples were frozen in liquid nitrogen,
crushed into powder in a mortar, and homogenized in
500μl homogenizing buﬀer (100μl Protease Inhibitor Cock-
tail [Sigma-Aldrich, St. Louis, MO] in 20ml 0.05M PB). Tis-
sue homogenates were centrifuged at 5000 rpm for 20min at
4°C. The HO1 and HO2 levels of the intestinal tissue samples
were determined by means of quantitative ELISA according
to the manufacturer’s instructions (SunRed Biotechnology,
Shanghai, China). Optical density was measured at
450 nm (Benchmark Microplate Reader; Bio-Rad, Budapest,
Hungary). The tissue HO1 and HO2 concentrations were
expressed as ng/mg protein.
2.8. Bradford Protein Micromethod for the Determination of
Tissue Protein Content. For the determination of protein con-
tent of tissue samples, a commercial protein assay kit was
used. Bradford reagent was added to each sample. After mix-
ing and following 10min incubation, the samples were
assayed spectrophotometrically at 595nm. Protein level was
expressed as mg protein/ml.
2.9. Statistical Analysis. Statistical analysis was performed
with one-way ANOVA and the Newman-Keuls test. All
analyses were carried out with GraphPad Prism 6.0 (Graph-
Pad Software, La Jolla, CA, USA). A probability of P < 0 05
was set as the level of signiﬁcance. All data were expressed
as means± SEM.
3. Results
3.1. Disease Characteristics in Diabetic Rats. The general
characteristics of the control and STZ-treated animals from
the acute and chronic diabetic experiments 3 days, 5 days,
10 days, and ten weeks after the STZ treatment are shown
in Tables 1 and 2. The chronic diabetic rats were character-
ized by a signiﬁcantly reduced body weight and an increased
blood glucose concentration (23.31± 0.53mM) as compared
to the age- and sex-matched controls.
3.2. Serum Level of HOs in Acute and Chronic Diabetic
Animals. In the serum samples, the HO1 expressed at higher
level than the HO2 (7.3± 0.32 versus 4.19± 0.19 ng/ml) in
the healthy animals of acute study (Figures 1(a) and
1(c)). Three days after the STZ treatment, the HO1
expression increased signiﬁcantly (P < 0 01) as compared
to controls, following a recovery in the 5-day-diabetic rats.
Moreover, it decreased further in the 10-day diabetics as
compared to control animals (Figure 1(a)). The expression
of HO1 was also decreased in the diabetic rats of the
chronic study as compared to controls; furthermore, the
serum HO1 concentration was not signiﬁcantly diﬀerent
in 10-week and 10-day diabetics (5.9± 1.09 versus 5.48±
0.3 ng/ml; Figures 1(a) and 1(b)).
In the case of HO2, similar changes were detected in the
serum samples of acute and chronic study. Brieﬂy, the HO2
level was signiﬁcantly decreased in 5-day-, 10-day-, and
10-week-diabetic animals as compared to their controls
(Figures 1(c) and 1(d)).
3.3. Evaluation of Myenteric Ganglia Representing HO-IR and
nNOS-HO-IR Neurons. Nitrergic myenteric neurons were
labelled by nNOS immunohistochemistry, whereas HO-
representing neurons were visualized by HO1 and HO2
immunohistochemistry. The densities of HO1- and HO2-
IR- as well as HO1- and HO2-representing nitrergic neurons
were evaluated per ganglia of the duodenum, ileum, and
colon in control and diabetic rats (Figures 2 and 3).
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The proportion of HO1-including myenteric ganglia was
diﬀerent in the various intestinal segments in control and
diabetic rats. They were observed in the highest percentage
in the colon (94%) and in the duodenum (88%) of controls.
However, only half of the ileal ganglia contained HO1-IR
neurons and from these ganglia only 16% represented
nNOS-HO1 colocalized neurons in the control rats
(Figures 4(a) and 4(c)).
In the diabetic group, all of the ileal ganglia included
HO1-IR neurons, and more than 60% of them also repre-
sented double-stained neurons. In the diabetic colon, all of
the myenteric ganglia included HO1-IR and also double-
stained neurons (100% versus 78% in controls), whereas in
the diabetic duodenum, the percentage of ganglia containing
HO1- and nNOS-HO1-IR neurons was slightly decreased
(88% versus 73% and 72% versus 61% in controls, resp.)
(Figures 4(a) and 4(c)).
The proportion of ganglia representing HO2- and nNOS-
HO2-IR neurons also varied in a region-dependent way. In
controls, 70–80% of the ganglia included HO2-IR neurons
in all gut segments with increased rate in diabetic animals
(Figure 4(b)). The lowest proportion of nNOS-HO2-
representing ganglia was observed in the ileum (27%) and
the highest in the colon (80%) of the control rats. In the
diabetic group, the rate of nNOS-HO2-including ganglia
increased in all intestinal segments; however, the greatest,
3-fold increase was observed in the ileum (Figure 4(d)).
3.4. Total Number of HO1-IR- and HO1-Representing
Nitrergic Neurons. The presence of HO1-IR neurons varied
distinctly in the diﬀerent gut segments even in the control
animals. The least HO1-IR cells were counted in the ileal
ganglia (1.44± 0.31), whereas 4-fold more HO1-IR neurons
were observed in the duodenum (6.04± 0.59) and 7-fold
more in the myenteric ganglia of the colon (10.08± 1.05).
Except for the duodenum, the total number of HO1-IR neu-
rons displayed a robust increase in the ileum (P < 0 0001)
and colon (P < 0 0001) of diabetic rats as compared
to the control data. The largest increase was observed
in the ileum, where almost 7-fold more HO1-IR neu-
rons were counted in the diabetics relative to controls
(9.62± 0.95 versus 1.44± 0.31) (Figure 5(a)).
The number of nNOS-HO1-IR myenteric neurons
showed a very similar distribution in the control group with
the lowest value in the ileal and the highest in the colonic
ganglia. Moreover, the number of nNOS-HO1 colocalized
neurons was also elevated 7-fold in the ileum of diabetics as
compared to controls (1.41± 0.27 versus 0.2± 0.07). In the
diabetic colon, the number of nNOS-HO1 colocalized neu-
rons was more than doubled, whereas in the duodenum of
diabetic rats it remained unchanged (Figure 5(b)). Since the
number of total HO1-IR and also that of the nNOS-HO1-
IR neurons represented similar alterations in the diﬀerent
gut segments of control and diabetic rats, therefore the pro-
portion of HO1-IR neurons colocalizing with nNOS did
not change in any of the diﬀerent intestinal regions. In the
ileum, only 18% of HO1-IR neurons were colocalized with
nNOS, whereas this ratio was around 30% in the ganglia
of the duodenum and colon under both experimental
conditions (Figure 5(c)).
Although the total numberofnNOS-IRneuronsdecreased
in all intestinal segments (9± 0.39 versus 7.53± 0.29 in the
duodenum, P < 0 01; 6.32± 0.35 versus 5.78± 0.27 in the
ileum; 9.5± 0.48 versus 7.38± 0.42 in the colon, P < 0 001),
the proportion of nNOS-IR neurons colocalizing with
HO1 exhibited a nearly 8-fold increase in the ileum and
a 3-fold increase in the colon of diabetics. This ratio was
barely 3% in the ileum and 23% in the colon of the con-
trol rats, whereas it was 24% and 72% in the diabetics,
respectively (Figure 5(d)).
3.5. Total Number of HO2-IR- and HO2-Representing
Nitrergic Neurons. The distribution of HO2-IR neurons also
displayed a region-dependent pattern in the control rats.
The bulk of the HO2-IR neurons was located in the colonic
ganglia (13.96± 1.73), whereas less than half as many were
Table 2: Weight and glycaemic characteristics of the animal groups of the chronic diabetic experiment.
Body weight (g)± SEM Blood glucose concentration (mM)± SEM
Initial Final Initial Final (average)
Controls (n = 5) 232.2± 7.29 486± 4.93∗∗∗∗ 7.08± 0.22 6.3± 0.13
STZ-treated diabetics (n = 6) 235.3± 10.48 382.7± 3.53∗∗∗∗oooo 6.6± 0.1 23.31± 0.53∗∗∗∗oooo
∗∗∗∗P < 0 0001 (initial versus ﬁnal), ooooP < 0 0001 (between ﬁnal values).
Table 1: Weight and glycaemic characteristics of the animal groups of the acute diabetic experiment.
Body weight (g)± SEM Blood glucose concentration (mM)± SEM
Initial Final Initial Final (average)
Controls (n = 5) 303.8± 9.46 339.5± 14.97 5.53± 0.24 5.63± 0.27
3-day diabetics (n = 5) 273.0± 11.15 274.3± 8.09 6.17± 0.37 23.03± 2.63∗∗∗∗
5-day diabetics (n = 5) 293± 13.7 301.7± 11.63 5.87± 0.29 23.14± 2.01∗∗∗∗
10-day diabetics (n = 5) 310.5± 4.27 346± 9.06 4.9± 0.29 23.95± 1.18∗∗∗∗
∗∗∗∗P < 0 0001 (initial versus ﬁnal).
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counted in the myenteric ganglia of the ileum and the duode-
num. In the diabetic rats, the total number of HO2-IR neu-
rons increased in the diﬀerent gut segments; however, the
increase was signiﬁcant only in the ileum (P < 0 01), where
the HO2-IR neuronal number was doubled relative to
controls (11.94± 1.24 versus 5.85± 0.85) (Figure 6(a)). The
number of nNOS-HO2-IR myenteric neurons represented
similar expression in controls, where the majority of the colo-
calized neurons also occurred in the ganglia of the colon
(4.32± 0.64), whereas an average of 0-1 cells was found in
the ileal and duodenal ganglia. Moreover, the number of
Figure 3: Representative ﬂuorescent micrograph of a whole-mount
preparation of myenteric ganglia from the duodenum of a diabetic
rat after nNOS-HO2 immunohistochemistry. Stars indicate
neurons that labelled for nNOS only, open arrows show neurons
that labelled for HO2 only, and solid arrows point to myenteric
neurons that double-labelled for both nNOS and HO2. Scale
bar: 50 μm.
Figure 2: Representative ﬂuorescent micrograph of a whole-mount
preparation of myenteric ganglia from the colon of a diabetic rat
after nNOS-HO1 immunohistochemistry. Stars indicate neurons
that labelled for nNOS only, open arrows show neurons that
labelled for HO1 only, and the solid arrow points to a
myenteric neuron that double-labelled for both nNOS and
HO1. Scale bar: 50μm.
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Figure 1: The serum level of HO1 and HO2 in acute (a, c) and chronic (b, d) diabetic rats. The HO1 expression increased signiﬁcantly in the
3-day diabetics with a recovery in the 5-day-diabetic rats, and it decreased further in the 10-day-diabetic animals as compared to the
controls (a). The serum HO1 level was almost the same in the 10-week and the 10-day diabetics (a, b). The serum concentration of
HO2 was also decreased in 5-day-, 10-day-, and 10-week-diabetic animals as compared to their controls (c, d). Data are
expressed as means± SEM. ∗∗P < 0 01 (compared to the controls), oP < 0 05; ooP < 0 01; ooooP < 0 0001 (compared to the 3-day
diabetics). C: controls; 3dD: 3-day diabetics; 5dD: 5-day diabetics; 10dD: 10-day diabetics; D: 10-week diabetics.
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nNOS-HO2 colocalized neurons was also elevated more than
6-fold in the ileum of diabetics as compared to controls (2.65
± 0.34 versus 0.42± 0.11; P < 0 001) (Figure 6(b)). Since the
number of total HO2-IR and also that of the nNOS-HO2-
IR neurons did not alter signiﬁcantly in the duodenum and
colon of control and diabetic rats, therefore the proportion
of HO2-IR neurons colocalizing with nNOS remained
unchanged in these intestinal regions. In the duodenum
28–30%, whereas in the colon 33–39% of HO2-IR neurons
were colocalized with nNOS under both experimental condi-
tions. However, this proportion was 6% in the ileum of the
control rats with a pronounced increase in the same segment
of diabetics (24%; P < 0 001) (Figure 6(c)).
Although the total number of nNOS-IR neurons
decreased in all intestinal regions (10.39± 0.51 versus
7.96± 0.44 in the duodenum, P < 0 01; 7.33± 0.42 versus
6.23± 0.22 in the ileum, P < 0 05; 10.48± 0.69 versus 8.08±
0.69 in the colon, P < 0 01), however, the proportion of
nNOS-IR neurons colocalizing with HO2 was deﬁnitely
increased in all gut segments of the diabetic group. The
largest, nearly a 7-fold increase, in this ratio was observed
in the ileum (40% versus 6%), but signiﬁcant increases were
also shown in the duodenum (22% versus 9%) and the colon
(68% versus 44%) of diabetics as compared to controls
(Figure 6(d)).
3.6. Tissue Level of HOs. In the tissue homogenates including
the smooth muscle layers of the intestinal wall and the
myenteric plexus, the expressional patterns of HO1 and
HO2 were strictly region dependent in the healthy animals
of chronic study. The highest concentrations of HO
enzymes were detected in the tissue homogenates of the
control duodenum with 46.35± 3.22 ng/mg protein in the
case of HO1 and 42.72± 3.53 ng/mg protein in the case
of HO2 (Figures 7(a) and 7(b)). In the ileum and colon
of controls, the tissue level of HOs was signiﬁcantly lower
than in the duodenum. In the 10-week diabetics, the
duodenum was the only gut segment where the tissue levels
of HOs decreased strongly (24.35± 1.12 ng/mg protein in
the case of HO1 and 28.44± 0.97 ng/mg protein in the case
of HO2), whereas they remained unchanged in the ileum
and colon (Figures 7(a) and 7(b)).
Since the changes in the total number of HO-IR- and
HO-representing nitrergic neurons was the most elevated in
the ileum of 10-week-diabetic rats, therefore we chose this
particular gut segment also from the acute study to
0
10
20
30
40
50
60
70
80
90
100
C D
Duodenum
C D
Ileum
C D
Colon
G
an
gl
ia
 c
on
ta
in
in
g 
H
O
1-
IR
 n
eu
ro
ns
 (%
)
(a)
0
10
20
30
40
50
60
70
80
90
100
C D
Duodenum
C D
Ileum
C D
Colon
G
an
gl
ia
 c
on
ta
in
in
g 
H
O
2-
IR
 n
eu
ro
ns
 (%
)
(b)
0
10
20
30
40
50
60
70
80
90
100
C D
Duodenum
C D
Ileum
C D
Colon
G
an
gl
ia
 c
on
ta
in
in
g 
nN
O
S-
H
O
1-
IR
 n
eu
ro
ns
 (%
)
(c)
0
10
20
30
40
50
60
70
80
90
100
C D
Duodenum
C D
Ileum
C D
Colon
G
an
gl
ia
 c
on
ta
in
in
g 
nN
O
S-
H
O
2-
IR
 n
eu
ro
ns
 (%
)
(d)
Figure 4: Percentage of myenteric ganglia containing HO1-IR (a), HO2-IR (b), nNOS-HO1-IR (c), and nNOS-HO2-IR (d) neurons. Only
half of the ileal ganglia contained HO1-IR neurons, and from these only 16% of the ganglia represented double-stained neurons in the
control rats. In the diabetic group, all of the ileal and colonic ganglia included HO1-IR neurons, and from these more than 60% of ileal
and 100% of colonic ganglia also represented the double-stained neurons. More than 70% of ganglia represented HO2-IR neurons under
both experimental conditions, and a large increase in the proportion of ganglia containing double-stained neurons was revealed in diabetic
state. C: controls; D: diabetics.
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measure the tissue level of HOs. In the tissue homogenates
of the ileum, the HO2 expressed at higher level than the
HO1 (26.94± 0.81 versus 20.55± 1.49 ng/mg protein) in
the healthy animals of the acute study. The acute hyper-
glycaemia did inﬂuence neither the HO1 nor the HO2
expression 3, 5, or 10 days after the STZ treatment as
compared to controls (19.35± 0.98 versus 18.09± 0.77 ver-
sus 18.76± 1.23 ng/mg protein in the case of HO1 and
27.76± 0.92 versus 28.66± 1.02 versus 27.72± 1.31 ng/mg
protein in the case of HO2, resp.).
4. Discussion
Based on our ﬁndings of immediate alterations after the onset
of hyperglycaemia, we presume that the increased HO1 level
in the serum of 3-day-diabetic rats can be a result of the stress
response caused by STZ treatment. This acute HO response
does not appear in the intestinal tissue homogenates (at least
in the ileum), which further strengthens our presumption.
This acute stress response appeared ﬁrstly in the systemic cir-
culation and not in the tissue of the gut and then it declines
gradually here in the 5- and 10-day-diabetic rats. Moreover,
the serum concentration of HO1 and HO2 were almost the
same in 10-day- and 10-week-diabetic animals.
In support of our earlier ﬁnding that the susceptibility of
nitrergic myenteric neurons to experimentally induced
diabetes is strictly regional [9], the present study provides
evidence of gut segment-speciﬁc diabetes-related induction
of the endogenous HO system and also the intestinal
region-dependent enhanced colocalization of HO1 and
HO2 with nNOS in myenteric neurons.
The occurrence of HO1- or HO2-containing myenteric
ganglia, furthermore the presence of those ganglia which
include nNOS-HO1 or nNOS-HO2 colocalized neurons,
was the most pronounced in the colon and the slightest in
the ileum of the control rats. Similarly, the number of
HO1- or HO2-IR and nNOS-HO1 or nNOS-HO2-IR neu-
rons was the highest in the colon and the lowest in the ileum
under control conditions. Interestingly, in the duodenum of
controls, although the number of HO1-IR or HO2-IR and
nNOS-HO1-IR or nNOS-HO2-IR neurons was less than in
the colon, still the presence of either HO-IR or nNOS-HO-
IR neurons representing myenteric ganglia was nearly as
explicit as in the colon.
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Figure 5: Quantitative evaluation of the total number of HO1-IR neurons (a), the number of nNOS-HO1-IR neurons (b), the proportion of
HO1-IR neurons colocalizing with nNOS (c), and the proportion of nNOS-IR neurons colocalizing with HO1 (d) in the myenteric ganglia of
the duodenum, ileum, and colon of control and diabetic rats. Except for the duodenum, the total number of HO1-IR neurons and the number
of nNOS-HO1-IR myenteric neurons displayed a robust increase in the ileum and colon of diabetic rats. The percentage of HO1-IR neurons
colocalizing with nNOS did not change in the diﬀerent intestinal segments. However, the proportion of nNOS-IR neurons colocalizing with
HO1 exhibited a nearly 8-fold increase in the ileum and a more than 2-fold increase in the colon of diabetics. Data are expressed as means
± SEM. ∗∗P < 0 01, ∗∗∗P < 0 001, and ∗∗∗∗P < 0 0001 (between controls and diabetics). C: controls; D: diabetics.
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Figure 6: Quantitative evaluation of the total number of HO2-IR neurons (a), the number of nNOS-HO2-IR neurons (b), the proportion of
HO2-IR neurons colocalizing with nNOS (c), and the proportion of nNOS-IR neurons colocalizing with HO2 (d) in the myenteric ganglia of
the duodenum, ileum, and colon of control and diabetic rats. The total number of HO2-IR neurons and the number of nNOS-HO2-IR
myenteric neurons largely increased in the ileum of diabetic rats. The percentage of HO2-IR neurons colocalizing with nNOS
was elevated only in the diabetic ileum. However, the proportion of nNOS-IR neurons colocalizing with HO2 was enhanced in
each gut segment of diabetics. The largest increase, more than 6-fold, was observed in the ileal ganglia. Data are expressed as
means± SEM. ∗P < 0 05, ∗∗P < 0 01, ∗∗∗P < 0 001, and ∗∗∗∗P < 0 0001 (between controls and diabetics). C: controls; D: diabetics.
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Figure 7: The tissue level of HO1 (a) and HO2 (b) in the diﬀerent gut segments of control and diabetic rats. The levels of HO1 and HO2 were
the highest in the tissue homogenates from the duodenum of controls and decreased to the distal part of the GI tract. In the diabetic rats, a
statistically intense decrease was observed in the level of HO1 and HO2 in the tissue homogenates of the duodenum but not in those of the
ileum and colon. Data are expressed as means± SEM. ∗∗∗∗P < 0 0001 (between controls and diabetics), ooooP < 0 0001 (between diﬀerent gut
segments of controls). C: controls; D: diabetics.
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Even under physiological conditions, these gut segment-
speciﬁc diﬀerences raise the question of why the myenteric
ganglia and nitrergic neurons are distributed diﬀerently,
depending on their intestinal location. It is well established
that the anatomical, functional, and pathological regionality
of the GI tract develops under strict genetic control
[43, 44], which in itself can be responsible for the unique fea-
tures of the enteric neurons in a healthy state and for their
diﬀerent susceptibilities to pathological insults in diﬀerent
gut segments. Emerging evidences [45, 46] conﬁrm that the
diﬀerent degrees of susceptibility of enteric neurons to a
pathological stimulus such as hyperglycaemia might be
related to the prevalence of bacteria in the diﬀerent parts of
the GI tract, which among others give rise to major diﬀer-
ences in the intestinal redox status and the oxygen supply
of the small and large intestine [47–49]. The microﬂora of
facultative bacteria expands during infancy and creates a
reducing environment that supports the population of the
gut by anaerobic strains, inducing a deep anaerobic state in
the distal intestine. The prooxidant environment of the colon
as compared to the small intestine may also contribute to
greater cancer susceptibility [48]. In our recent study [13],
we already demonstrated evidence of gut region-speciﬁc
accumulation of reactive oxygen species and also that
enhanced oxidative stress leads to regionally distinct activa-
tion of antioxidant and apoptotic marker molecules in prox-
imal and distal part of the gut in rats with STZ-induced
diabetes. There was no signiﬁcant change in peroxynitrite
level in the duodenum in any of the examined groups.
However, in the diabetic colon, the peroxynitrite level was
signiﬁcantly increased, and the presence of severe necrosis
was also conﬁrmed by electron microscopy [13]. These
data also suggest that the distal part of the gut is more
vulnerable than the proximal to oxidative stress.
Therefore, we suppose that in the colon, where the base-
line oxidative environment is far from optimal, the basal
expression of HOs as essential players of the endogenous
defense mechanisms is the most pronounced. In another
study by Battish et al. [50], region-speciﬁc coexistence of
HO2 with nNOS was also observed in the opossum anorec-
tum, where the high percentage of colocalization in the
myenteric plexus fell from almost 100% in the internal anal
sphincter to 56% proximally in the rectum. This supports
our ﬁndings that 44% of nNOS-IR neurons are also coloca-
lized with HO2 in the colon of the control rats.
We also suggest that in the ileum the presence of the HO
proteins is extremely low in controls, which may result in
much lower protection against diﬀerent pathological stimuli.
Other groups have also demonstrated a hardly detectable
expression of HO1 protein in mucosal epithelial cells of
the ileum, and these were much more vulnerable to inju-
ries by haemorrhagic shock [51] or septic damage [52].
Miller et al. [53] detected little if any immunoreactivity
of HO1 in the human antrum and jejunum. However,
Donat et al. [54] reported that only 10% of HO2-positive
neurons contained NOS in rat ileum, which is in good
correlation with our results.
We also assume that as a result of the adequate oxidative
environment and deﬁnite baseline expression of HOs and
their colocalization with nNOS in the myenteric ganglia in
the proximal small intestine, the nitrergic neurons get greater
protection and can tolerate hyperglycaemia-related oxidative
stress better in the duodenum. This is supported by evidence
that despite the impairment of nNOS pathways in STZ-
induced diabetic rats, the nitrergic myenteric neurons did
not die in the duodenum, unlike the other gut segments [9].
Moreover, the highest level of HO1 and HO2 expression
in the tissue homogenates of the control duodenum (includ-
ing the smooth muscle layers of the gut wall and the myen-
teric plexus between them) also highlights an intensiﬁed
protective environment in this particular gut segment and
emphasizes the importance of the neuronal microenviron-
ment [10, 12]. Microsomal HO activity was also highest in
the duodenal mucosa, where absorption of hemoglobin iron
is reported to be most eﬀective, and progressively fell in more
caudal intestinal segments [55].
In diabetics, the number of HO1- or HO2-representing
myenteric ganglia, as well as the number of those ganglia
which contain nNOS-HO1 or nNOS-HO2 colocalized neu-
rons, was markedly elevated in the ileum. Likewise, the num-
ber of HO1- or HO2-IR and nNOS-HO1 or nNOS-HO2-IR
neurons was altered in a region-dependent manner in dia-
betic rats. The most intensiﬁed enhancement was also
observed in the ileum of diabetics, which highlights the high-
est concern of this intestinal region in diabetes-related dam-
age, also predicted in our earlier study [11]. Using a type 1
diabetic rat model to analyse the composition of faeces-
associated microbiota, we demonstrated that only ileal
samples from diabetic rats exhibited striking, but massive
invasion (31%) of the pathogen genus Klebsiella [11]. It was
recently reported that intestinal HO1 is induced by the
enteric microbiota and modulates the macrophages bacteri-
cidal activity, suggesting its importance in maintaining
homeostasis [56]. On the base of this, we suggest that the
diabetes-related massive changes in the composition of the
ileal gut microbiota [11] may contribute to the enhanced
mucosal immune response and the greatest induction of
endogenous HO system in this particular gut segment.
As regards the details of segment-speciﬁc diabetic
alterations, in the diabetic ileum, both the HO1-IR and the
nNOS-HO1-IR neuronal number was enhanced 7-fold,
and the number of nNOS-HO2-IR neurons also increased
6-fold as compared to controls. Nevertheless, the total num-
ber of nNOS neurons decreased in all intestinal segments of
diabetics, conﬁrming our earlier ﬁndings [9]. Accordingly,
much more nitrergic neurons also become HO-IR; thus,
many of them start to product HO enzymes. Moreover, this
also means that those nNOS-positive neurons which are
not colocalized with HOs will be destroyed. Similar alter-
ations were seen in the colon, where besides a 22% decrease
in the nNOS number, a more than 50% increase was demon-
strated in the number of nNOS-HO1-IR neurons, from
which we assume that HO-containing nitrergic neurons
enjoy higher protection, whereas the others are heavily
aﬀected by diabetic damage. In the diabetic duodenum,
besides a decreasing number of nNOS neurons, the number
of colocalized myenteric neurons did not alter signiﬁcantly,
leading to the same conclusion. However, based on the study
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of Izbéki et al. [9], in which the duodenum was the only gut
segment where the decrease of NADPHd-positive neuronal
number was not followed by a decrease in the number of total
myenteric neurons, we suppose that in the present study, the
reduced number of nNOS neurons means cell loss in the
diabetic ileum and colon but a change in neurochemical
character in the duodenum. Among others, the neuronal
microenvironment-like capillaries of the gut wall or intes-
tinal microbiota of the diabetic duodenum were broadly
unharmed [10, 11].
Diabetic gastroparesis is a widely researched complica-
tion of diabetes, in which the interstitial cells of Cajal respon-
sible for normal gastric emptying are largely damaged [7]. In
the diabetic gastric fundus, the number of nNOS-IR neurons
was decreased, nNOS expression was downregulated [57],
and an impairment in nitrergic relaxation was also reported
contributing to the development of diabetic gastroparesis in
rats [58]. In mouse models of diabetes, increased expression
of antioxidants such as HO1 protected interstitial cells of
Cajal from oxidative stress and reversed diabetic gastropar-
esis [33]. Recent discovery shows that HO gives neuroprotec-
tion by controlling redox formation and reducing production
of tumor necrosis factor alpha (TNFα) [59]. In the light of
these ﬁndings, the role of the endogenous HO system in the
protection of intestinal motility in diabetics is further
strengthened. However, the literary data suggest that TNF
may also be capable of exerting opposite eﬀects, which could
depend on parameters such as the site, degree, and duration
of the ischemic period, the amount of TNF production, the
expression level of the two TNF receptors, and the cellular
environment of aﬀected neurons [60]. It has been demon-
strated that the involvement of the TNF/TNF-receptor
system and opposing actions of the two TNF receptors
resulting neuronal damage or promoting neuroprotection
via diﬀerent signalling pathways [60–62].
At present, only limited data are available about the
diabetes-related expressional changes of HOs in diﬀerent
gut segments. In the STZ rat model, the nitrergic myenteric
neurons that also express HO2 were more resistant to the
eﬀects of diabetes and less likely to undergo apoptosis [36].
In the diabetic ileum, this study revealed an increased size
of neuronal cell body in nNOS-IR neurons, while HO2-IR
neurons remained unaﬀected. Double-labelling studies con-
ﬁrmed that the diabetes-induced change in size was conﬁned
to nNOS-IR neurons that did not contain HO2.
The induction of the HO system by agents (such as
several redox signals, hypoxia, or endotoxin) has been sug-
gested to be an initial event in the development of an adaptive
response to oxidative stress and inﬂammatory events in type
1 and type 2 diabetes [19, 63–66]. Bacterial endotoxin
induces HO mRNA accumulation [67] and directly stimu-
lates HO activity in macrophages and the liver [68]. Emerg-
ing evidence indicates that the upregulation of the HO
system and related products increases pancreatic beta cell
insulin release and reduces hyperglycaemia in diﬀerent ani-
mal models [22]. The HO system is also upregulated in short
term diabetes, leading to HO and NO interactions, which
may modulate vascular function in the retina [69, 70]. Cheng
et al. [71] reported that hypoxia-inducible factor-1α target
genes like HO also contribute to retinal neuroprotection.
It has also been demonstrated that NO and NO donors
are capable of inducing HO1 protein expression, in a
mechanism depending on the de novo synthesis of RNA
and protein. Thus, it is postulated that NO may serve as
a signaling molecule in the modulation of the tissue stress
response [72].
5. Conclusions
In conclusion, our present ﬁndings emphasize that the
endogenous HO system of the GI tract is also a target of dia-
betic damage. In addition, the evidences published here have
revealed for the ﬁrst time the intestinal region-dependent
induction of the HO system as well as the segment-speciﬁc
enhanced colocalization of HO1 and HO2 with nNOS in
myenteric neurons. Obviously, the functional consequences
of these diabetes-related alterations, namely, the possible
interactions between the carbon monoxide and nitric oxide
pathways produced by them in enteric neurons to regulate
various GI functions demand further investigations.
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